

From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn>
To: "Najib Aziz" <naziz@ucla.edu>
Cc: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>,
"Dr. Henry J. Heimlich" <Heimlich@iglou.com>,
"Henry J. Heimlich" <heimlich@juno.com>,
"Debbie" <dmathies@microimmun.medsch.UCLA.edu>

Date: Fri, 21 Nov 1997 08:03:39 +0800

Subject: Send reagents

Message-ID: <199711202355.HAA03512@gzsums.edu.cn >

Received: from mx2.boston.juno.com (mx2.boston.juno.com [207.205.100.51])
by m5.boston.juno.com (8.8.6.Beta0/8.8.6.Beta0/2.0.kim) with ESMTTP id TAAAA05939
for <heimlich@juno.com>; Thu, 20 Nov 1997 19:02:56 -0500 (EST)

Received: from gzsums.edu.cn (letter.gzsums.edu.cn [202.116.96.34])
by mx2.boston.juno.com (8.8.6.Beta0/8.8.6.Beta0/2.0.kim) with SMTP id TAAAA23525
for <heimlich@juno.com>; Thu, 20 Nov 1997 19:02:39 -0500 (EST)

Received: from gzsums.edu.cn.gzsums.edu.cn by gzsums.edu.cn (SMI-8.6/SMI-SVR4)
id HAA03512; Fri, 21 Nov 1997 07:55:42 +0800

X-Mailer: Microsoft Internet Mail 4.70.1155

Return-path: <chenxp@gzsums.edu.cn>

Dear Dr. Aziz:

Dr. Fahey's visit to Guangzhou last month was very helpful to our project of malariotherapy for HIV infection. Now we will start the next batch of clinical trials very soon. So I hope that you send us the following reagents as soon as you can by Federal Express or other express.

1. Kits for flow cytometry including CD4, CD8, CD25, HLA-DR and CD4 PCD

(apoptosis) testings.

2. Kits for activation markers including NPT, B-2-M, TNF-a, IFN-r, sTNF-aRII, sIL-2R and plussing IL-2 (if possible, plussing IFN-a, IL-6 and IL-10) testings.

By the way, I have now another hypothesis that malaria stimulates a shift from Th2 to Th1 pattern of immune response in HIV patient. I believe that it will be confirmed by our coming trials.

Best regards.

Dr. Chen Xiao Ping
Research Associate Professor

Juno e-mail printed Wed, 6 Nov 2002 15:30:36 , page 1

From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn>
 To: <helmlich@iglou.com>
 Cc: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>,
 "Henry J. Helmlich" <helmlich@juno.com>

Date: Thu, 18 Dec 1997 08:27:41 +0800

Subject: Re: Patient selection

Message-ID: <199712190035.IAA18221@gzsums.edu.cn >

Received: from mx1.boston.juno.com (mx1.boston.juno.com [205.231.100.50])
 by m5.boston.juno.com (8.8.6.Beta0/8.8.6.Beta0/2.0.kim) with ESMTTP id TAAAA12499
 for <helmlich@juno.com>; Thu, 18 Dec 1997 19:42:52 -0500 (EST)

Received: from gzsums.edu.cn (letter.gzsums.edu.cn [202.116.86.34])
 by mx1.boston.juno.com (8.8.6.Beta0/8.8.6.Beta0/2.0.kim) with SMTP id TAAAA01746
 for <helmlich@juno.com>; Thu, 18 Dec 1997 19:42:28 -0500 (EST)

Received: from gzsums.edu.cn.gzsums.edu.cn by gzsums.edu.cn (SMI-8.6/SMI-SVR4)
 id IAA18221; Fri, 19 Dec 1997 08:35:58 +0800

X-Mailer: Microsoft Internet Mail 4.70.1155

Return-path: <chenxp@gzsums.edu.cn>

Dear Dr. Helmlich and Dr. Spletzer:

We have 20 HIV patients at hand, among them 3 are sexually transmitted and others are drug users. The most important thing right now is that we are waiting for the reagents from UCLA (and we are dealing with the customs issue) to screen CD4 levels of the patients due to other criteria of patient selection. According to the principal of scientific research, we need the same batch (or the same resource) of reagents to test patients before and after treatment. All things are progressing here in Guangzhou.

The number of tested and officially reported HIV positive patients in China is about 2800 by now. All other numbers are estimated and I believe that nobodies know the exact number. But we can say that HIV/AIDS has been a real problem in China; in some regions such as Yunnan Province the problem has been really severe.

Yes, we have received the funds from the Helmlich Institute.

Merry Christmas!

Dr. Chen Xiao Ping

> From: Dr. Henry J. Helmlich <helmlich@iglou.com>
 > To: chenxp@gzsums.edu.cn
 > Subject: Patient selection
 > Date: Thursday, December 18, 1997 8:57 AM
 >
 > Dear Dr. Chen,
 >
 > We received copies of the e-mail concerning the import of test
 > reagents, and are glad to see that things are proceeding. However,
 > we are still interested in knowing how patient selection is going,
 > especially for the sexually transmitted cases.
 >
 > A recent lecture by R. Peter Piot, Executive Director of the UNAIDS
 > program, stated the following:

Juno e-mail printed Wed, 6 Nov 2002 15:30:36 , page 2

>
> "In China - on the other hand, dramatic developments with consistent
> increase in HIV infections may be expected in the coming future.
> The national AIDS committee in China just released estimates projecting
> the number of people living with HIV/AIDS rising from 400,000 at the
> end of 1997 to about 1.2 million by the year 2000. Whereas most of the
> HIV infections in the past occurred in injecting drug users, the
> dramatic increases in sexually transmitted diseases in China suggest
> that the main mode of transmission of HIV may rapidly change in the
> coming years. STDs are becoming particularly widespread in China's
> coastal regions with their booming economies, growing disparities in
> wealth, and vast population movements. A study in Yunnan Province,
> for example, has already shown how easily the epidemic can break out
> of the drug user group to their sex partners and ultimately their
> children. Here around 7% of the spouses of infected drug users are
> already infected with HIV. As elsewhere in Asia and the Pacific,
> where the tiger economies are bringing in new wealth, the potential
> also exists for an acceleration of the epidemic."

>
> Do you feel this is accurate?

>
> We hope that everything else is going well for you and your colleagues.

>
> Happy holidays!

>
> Eric G. Spletzer, Ph.D.

>
> P.S. Did the funds we wired make to your account?

Juno e-mail printed Wed, 6 Nov 2002 15:33:07 , page 1

From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn>
 To: "Mathieson, Deborah" <dmathies@microimmun.medsch.UCLA.edu>
 Cc: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>,
 "Dr. Henry J. Heimlich" <Heimlich@iglou.com>,
 "Evelyn" <enajera@microimmun.medsch.UCLA.edu>,
 "Henry J. Heimlich" <heimlich@juno.com>,
 "Najib Aziz" <naziz@ucla.edu>
 Date: Thu, 25 Dec 1997 11:30:51 +0800
 Subject: Re: Dr. Fahey's letter of Nov. 13
 Message-ID: <199712250334.LAA15457@gzsums.edu.cn >
 Received: from mx1.boston.juno.com (mx1.boston.juno.com [205.231.100.50])
 by m5.boston.juno.com (8.8.6.Beta0/8.8.6.Beta0/2.0.kim) with ESMTP id WAAAA04542
 for <heimlich@juno.com>; Wed, 24 Dec 1997 22:44:41 -0500 (EST)
 Received: from gzsums.edu.cn (info.gzsums.edu.cn [202.116.96.34])
 by mx1.boston.juno.com (8.8.6.Beta0/8.8.6.Beta0/2.0.kim) with SMTP id WAAAA13249
 for <heimlich@juno.com>; Wed, 24 Dec 1997 22:44:32 -0500 (EST)
 Received: from gzsums.edu.cn.gzsums.edu.cn by gzsums.edu.cn (SMI-8.8/SMI-SVR4)
 id LAA15457; Thu, 25 Dec 1997 11:34:26 +0800
 X-Mailer: Microsoft Internet Mail 4.70.1155
 Return-path: <chenxp@gzsums.edu.cn>

Dear Dr. Fahey:

Thank you very much for your letter of November 13 and for your appreciation of Guangzhou and the Municipal Health and Anti-Epidemic Station of Guangzhou.

Yes, the time was too short to arrange a visit for you to Guangzhou Yishou Hospital where HIV patients receive malaria therapy. There are at least two clinical doctors specially staying at the hospital for the therapy when patients are during the febrile periods with malarial infection and some times I stay there too (by the way, I was a physician for infectious diseases from 1982 to 1988). All individuals are clear in their responsibilities in the studies because we have a research contract in which all participants signed their names.

The technician who is in charge of flow cytometry in Professor Yu Chun Shan's laboratory now will to accept HIV positive samples after your visit and my contact with him a couple of times. We are planning to treat 10 patients, among them 8 are drug users, other two are sexually transmitted; we have no control group this time according to our protocol. Thank you again for your reminding us of the CD4 measurements on two blood samples before starting the treatment and other issues.

We are still dealing with the customs tax-free procedure for the reagents; it takes a period of time but we will let you know as soon as we have dealt it up.

Sincerely, you are warmly welcome to visit Guangzhou again and I suggest that if possible, please come together with Dr. Heimlich when the patients are infected with malaria.

Juno e-mail printed Wed, 6 Nov 2002 15:33:07 , page 2

Merry Christmas and happy New Year!

Dr. Chen Xiao Ping .
Chief, Department of Microbiology
The Municipal Health and
Anti-Epidemic Station of Guangzhou

Juno e-mail printed Wed, 6 Nov 2002 15:38:19 , page 1

From: "Najera, Evelyn" <ENAJERA@microimmun.medsch.ucla.edu>
 To: Chen Xiao Ping <chenxp@gzsums.edu.cn>
 Cc: "Mathieson, Deborah" <DMATHIES@microimmun.medsch.ucla.edu>,
 "Henry J. Heimlich" <heimlich@juno.com>
 Date: Mon, 12 Jan 98 12:04:00 PST
 Subject: Reagents and customs
 Message-ID: <34BA77A9@deans.medsch.ucla.edu>
 Received: from mx1.boston.juno.com (mx1.boston.juno.com [205.231.100.50])
 by m5.boston.juno.com (8.8.6.Beta0/8.8.6.Beta0/2.0.kim) with ESMTP id PAAAA09546
 for <heimlich@juno.com>; Mon, 12 Jan 1998 15:03:03 -0500 (EST)
 Received: from MedHub.medctr.ucla.edu (medhub.medctr.ucla.edu [149.142.194.60])
 by mx1.boston.juno.com (8.8.6.Beta0/8.8.6.Beta0/2.0.kim) with SMTP id PAAAA19354
 for <heimlich@juno.com>; Mon, 12 Jan 1998 15:03:07 -0500 (EST)
 Received: from deans.medsch.ucla.edu by MedHub.medctr.ucla.edu (SMI-8.6/SMI-SVR4)
 id MAA27472; Mon, 12 Jan 1998 12:02:15 -0800
 Received: by deans.medsch.ucla.edu with Microsoft Mail
 id <34BA77A9@deans.medsch.ucla.edu>; Mon, 12 Jan 98 12:06:01 PST
 X-Mailer: Microsoft Mail V3.0
 Return-path: <ENAJERA@microimmun.medsch.ucla.edu>

Dear Dr. Chen:

I hope you are having a pleasant beginning in 1998. Thank you for the photos and for your wishes. I will also forward the photos to Matt which I am sure he will be pleased to receive.

Thank you for sending such thorough explanation on your customs situation.

You may also want to speak with 2 of our trainees in China conducting work there. They have been able to obtain clearance through customs with the same documentation I provided to you and DHL. They may be able to provide some advise on the procedure from their end:

- 1) Dr. Hong Wang—School of Basic Medical Sciences
 Tel. 86-106-209-1155
 Fax 86-106-209-1436
- 2) Dr. Xudong Lin—Chinese Academy of Preventive Medicine
 Tel. 86-106-353-8621-71
 Fax. 86-106-302-2960

In the meantime, I will discuss this issue with Dr. Fahey and we will be in touch with you.

Best Regards,
 Evelyn

From: Chen Xiao Ping
 To: Mathieson, Deborah
 Cc: Najib Aziz; Dr. Eric G. Spletzer; Dr. Henry J. Heimlich; Evelyn;
 Henry

Juno e-mail printed Wed, 6 Nov 2002 15:38:19 , page 2

J. Heimlich
 Subject: Reagents and customs
 Date: Wednesday, January 07, 1998 9:18AM

Dear Dr. Fahey:

It is complicated to deal with customs duty-free in China. We have not known the procedure until just now. We need in advance your donation letter (by express, not by fax) in which all reagents and their values should be listed before you ship them. After we receive your donation letter, we need to apply customs duty-free at Guangdong Provincial Government with your letter and only we get the approval from the government can we let you know the time to ship reagents. The customs authorities will let us know when reagents reach Guangzhou Customs. Finally we need to go there to deal with the duty-free procedure with your letter and documentation of the government and then take the reagents .

Each time we need to do all things mentioned above. So we hope you ship each time as many as you can. But we are urgent to need the reagents for flow cytometry, because they have to be real time testing.

An officer who is in charge of the issue at the government suggested that your donation letter should be written as follow (as reference, and he also suggested to have your signature in the letter, because you had a visit to our station and we have the document of your visit):

Donation Letter

Date...

Chen Xiao Ping, MD
 The Municipal Institute for Preventive Medicine of Guangzhou
 The Municipal Health and Anti-Epidemic Station of Guangzhou
 No. 23, 3rd Zhongshan Road
 Guangzhou 510080, The People's Republic of China
 ph: (20) 83828291
 fax: (20) 83815255

Dear Dr. Chen:

We are pleased to know that malariotherapy for HIV/AIDS has been conducting at your institute and some good results have been attained from the study.

In order to promote the global research of AIDS prevention and treatment, we decide to provide some reagents to help the research. These reagents are

purchased by Fogarty AIDS International Training and Research Program at UCLA and are given as a gift to the Municipal Institute for Preventive Medicine of Guangzhou, the Municipal Health and Anti-Epidemic Station of Guangzhou for special use on the research of malariotherapy for HIV/AIDS. Supplies have no commercial value and can not be sold in China.

Specifically the shipped package contains:

Item Description	Quantity	Cost
------------------	----------	------

.....

We hope you accept them.

Sincerely,

John L. Fahey, MD
Director, Fogarty Program
Director, Professor, CIRID

But you may write it in a formal and beautiful English. Thank you.

Happy New Year!

Dr. Chen Xiao Ping

Juno e-mail printed Wed, 6 Nov 2002 15:04:34 , page 1

From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn>
To: "Evelyn" <enajera@microimmun.medsch.UCLA.edu>
Cc: "Najib Aziz" <naziz@ucla.edu>, "Mathieson,
Deborah" <dmathies@microimmun.medsch.UCLA.edu>,
"Dr. Eric G. Spletzer" <egspletzer@hotmail.com>,
"Dr. Henry J. Heimlich" <Heimlich@iglou.com>,
"Henry J. Heimlich" <heimlich@juno.com>
Date: Sun, 18 Jan 1998 19:00:19 +0800
Subject: Reagents-urgent
Message-ID: <199801190159.JAA15106@gzsums.edu.cn >
Received: from mx4.boston.juno.com (mx4.boston.juno.com [207.205.100.53])
by mx5.boston.juno.com (8.8.8.Beta0/8.8.8.Beta0/2.0.kim) with ESMTP id VAAAA01567
for <heimlich@juno.com>; Sun, 18 Jan 1998 21:10:15 -0500 (EST)
Received: from gzsums.edu.cn (info.gzsums.edu.cn [202.116.96.34])
by mx4.boston.juno.com (8.8.8.Beta0/8.8.8.Beta0/2.0.kim) with SMTP id VAAAA01364
for <heimlich@juno.com>; Sun, 18 Jan 1998 21:10:10 -0500 (EST)
Received: from gzsums.edu.cn.gzsums.edu.cn by gzsums.edu.cn (SMI-8.6/SMI-SVR4)
id JAA15106; Mon, 19 Jan 1998 09:59:39 +0800
X-Mailer: Microsoft Internet Mail 4.70.1155
Return-path: <chenxp@gzsums.edu.cn>

Dear Evelyn:

Thank you for your email of Jan. 13 and for your all efforts on the
issue
of reagents. I have again contacted the officer at Guangdong Provincial
Government. He explained that it is the local government that manages the
issue of customs duty-free (not the Central Government) and he implied
that we should deal with the issue according to the regulations of
Guangdong Government not Beijing (local) Municipal Government.

We are very urgent to have the reagents for flow cytometry because they
are
real time testings and now we wait them for our clinical trial. Please
send
us the donation letter first by fax and then by express. I will let you
know the time to ship the reagents (especially the ones for cytometry)
through E-mail as soon as possible. Thank you again.

Best wishes

Dr. Chen Xiao Ping

Juno e-mail printed Mon, 16 Sep 2002 10:44:05 , page 1

From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn>
To: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>,
"Dr. Henry J. Heimlich" <Heimlich@iglou.com>,
"Henry J. Heimlich" <heimlich@juno.com>
Date: Sun, 8 Mar 1998 20:00:30 +0800
Subject: Fw: shipment return back to UCLA

> From: Najib Aziz <naziz@ucla.edu>
> To: chenxp@gzsums.edu.cn
> Subject: shipment return back to UCLA
> Date: Friday, March 13, 1998 6:31 AM
>
> Dear Dr.Chen.
>
> Unfortunately the shipment to you (Air Bill#1077268426) return back to
my
> lab by AIRBORN EXPRESS today.AIRBORN EXPRESS has written to us that the
> items in the package are unacceptable commodities by China and rejected
> from IEX Gateway. There are problems with the DHL Worldwide Express
> Federal Express . I am trying to find way to ship these items back to
you
> soon. If you have any question regarding shipment please Email me .
> Thanks
> Najib Aziz

Juno e-mail printed Mon, 16 Sep 2002 10:55:04 , page 1

From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn>
 To: "Najib Aziz" <naziz@ucla.edu>
 Cc: "Brian Ma" <pacbridge@aol.com>,
 "Henry J. Heimlich" <heimlich@juno.com>,
 "Dr. Henry J. Heimlich" <Heimlich@iglou.com>,
 "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>,
 <dmathies@microimmun.medsch.UCLA.edu>
 Date: Sat, 11 Apr 1998 11:07:01 +0800
 Subject: Re: Reagents

Dear Dr. Aziz:

I received the first package of reagents on April 9 (you sent on March 31).
 It took 9 days to reach me. I do not know whether these reagents are still useful because all bagged ice dissolved when I received them. But I can test them using blood samples taken from normal people before the clinical trial. Any way, I must thank you very very much, you have done your best. I do not begin the treatment until I receive your second package of reagents.
 Thank you again.

Best regards to you, Dr. Fahey and my other friends at UCLA!

Dr. Chen Xiao Ping
 Director, Center for AIDS Control & Research

> From: Najib Aziz <naziz@ucla.edu>
 > To: chenxp@gzsums.edu.cn
 > Cc: dmathies@microimmun.medsch.UCLA.edu; Dr. Eric G. Spletzer <egspletzer@hotmail.com>; Dr. Henry J. Heimlich <Heimlich@iglou.com>; Henry J. Heimlich <heimlich@juno.com>
 > Subject: Reagents
 > Date: Saturday, April 11, 1998 12:18 AM
 >
 > Dear Dr. Chen;
 >
 > The rest of your requested items shipped on Wednesday April 8, 1998 and you will have the package by Tuesday April 14, 1998. This package has the following items:
 > -IFN-gamma EIA one kit (96 tests)
 > -sTNF-RII EIA one kit (96 tests)
 > -sIL-2R EIA one kit (96 tests)
 > -Coulter Manual CD4 count one kit (50 tests)
 > -Propidium Iodide one vial.
 > The shipment number is 8392048630((DHL worldwide Express). If you have any question regarding the shipment, please E-mail me.
 > Thank You
 > Najib

Subject: Re: Viral Load Testing

Date: Fri, 25 Sep 1998 16:02:33 -0700

From: chenxp <chenxp@gzsums.edu.cn>

Organization: chenxp

To: HJ Heimlich <heimlich@iglou.com>

HJ Heimlich wrote:

>
> Dear Dr. Chen,
>
> We hope to approach the person sponsoring our malariotherapy for HIV
> research soon for more funding. This foundation has told that we will
> not be able to get any funding for additional patients until Dr.
> Heimlich and Dr. Fahey present the results on the current patients,
> especially the viral loads. In order to set up this funding, we must
> know as soon as possible about the viral loads. What arrangements have
> you made for the viral load testing? Have you talked to Dr. Fahey yet?
> If you have not had a chance to talk to him, please do so as soon as
> possible.
>
> I hope things are going well for you and your coworkers. We look
> forward to hearing from you soon.
>
> Best wishes,
>
> Eric

Dear Dr. Heimlich and Dr. Spletzer:

Thank you for your email. Shipment of HIV samples is complicated. We will discuss the detailed about viral load testing when Dr. Fahey visits Guangzhou next month. Here attaches Dr. Fahey's email.

Best regards and wishes.

Chen Xiao Ping, MD

Attached:

Subject: Letter

Date: Fri, 18 Sep 98 12:01:00 PDT

From: "John L. Fahey, M.D." <jlfahey@microimmun.medsch.ucla.edu>

To: "Chen Xiao Ping, M.D." <chenxp@gzsums.edu.cn>

September 18, 1998

Dear Dr. Chen,

I am writing to arrange a visit with you in Guangzhou on Wednesday, October 28, 1998. I am anxious to know how all of your work is going. It will be interesting to learn about your recent studies of HIV infection and of the progress of the malarial therapy study. Some of the reagents that we sent were to measure CD25 and HLA-DR expression on lymphocytes. Also, kits for TNFa, TNF-RII, neopterin and b2M determinations were provided. I am sending under separate cover data obtained at UCLA on the levels of these factors in a reference HIV negative population as well as in HIV positive individuals. We know that there are substantially fewer HIV+ persons in Guangzhou. However, it would be interesting to review your preliminary data with both HIV- and HIV+ populations in Guangzhou. We do not expect that the data would

be the same in both locations, but a look at the initial data might be advantageous at this time, particularly if more reagents will be needed. Separately, of course, there is the interest in the clinical and laboratory status of the participants in your study of malarial therapy. It would be interesting to know how many febrile episodes each of the recipients had and any other clinical manifestations of the malarial infection or of HIV induced AIDS. Also, the CD4 T-cell levels and other laboratory parameters that you have been able to measure should be quite interesting. I do hope that you will be willing to share that with me. We can discuss the shipment of samples for viral load determination. It would be reasonable to wait until I have visited Guangzhou before sending any samples here. I would be glad to talk more with you about that and any other matters that you wish during my visit to Guangzhou on October 28th.

My travel plans call for arriving on the same morning train as last March, but I should return to Hong Kong by the evening train on the 28th. That should provide 5 or 6 hours to review data, meet your colleagues and discuss future plans. I regret missing the opportunity to have one of the fabulous dinners that Guangzhou is famous for but I look forward to that on another visit.

Sincerely,

John L. Fahey, M.D.
Director, CIRID at UCLA
Chair, Clinical Immunology Committee, International
Union of Immunological Societies (IUIS)
JLF/kw

cc: Hong Bass, M.D., Ph.D.
Najib Aziz, M.D.
Barbara Hered

John L. Fahey, M.D.

From: John L. Fahey, M.D.
To: Chen Xiao Ping, M.D.
Cc: Najib; Barbara Hered; hbass
Date: Tuesday, November 10, 1998 11:39AM

Center for Interdisciplinary Research
in Immunology and Disease (CIRID)

November 10, 1998

VIA EMAIL

Chen Xiao Ping, M.D.
Department of Microbiology
The Municipal Health and Anti-Epidemic Station of Guangzhou
No. 23, 3rd Zhongshan Rd.
Guangzhou 510080, P.R. China

Dear Dr. Chen,

I want to follow-up on some of the many topics that we discussed on my visit on October 28th to the Municipal Health and Anti-epidemic Station in Guangzhou.

First of all, congratulations on your appointment as head of the HIV/AIDS Program in the Municipal Health and Anti-epidemic Station of Guangzhou. You certainly have developed substantial resources for evaluating HIV/AIDS and have developed innovative approaches to therapy. This certainly must be one of the most dynamic centers for HIV/AIDS research and education in all of China. I do hope you are able to continue doing your excellent work with malarial therapy.

It was kind of you to suggest using my name among the authors on the paper assembling data from the 2nd study. However, it is more appropriate if you simply acknowledge assistance of Dr. Najib Aziz and myself in some aspects of the study in an acknowledgment paragraph or at the end of your manuscript or abstract. You must understand that we want very much to see this study succeed but we think that we should not be among manuscript authors at this time.

I am quite willing to provide assistance in manuscript review and preparation of manuscripts that may be aimed at international or US journals. We are anxious that the findings be clearly presented in a balanced manner so that they can be readily judged by the many people interested in the treatment of HIV/AIDS.

I know that you will need some more reagents. We would be glad to send you some more reagents for your flow cytometry. It was not clear to me when I was there what the specific needs were. I gather you may need more CD8 reagents but you should send an email to Barbara Hered and Najib Aziz about this. We do not want to order large amounts in advance because, if they are used slowly, they may become outdated. Instead, we prefer to send you more reagents in the future as they become necessary.

Testing of reference populations of people of approximately the same age as your patients was one of the topics we discussed on October 28th. You have made a good start. At least 20 people should be tested for normative values of all the measurements that are being made in the HIV population. Also, to check on consistency of testing you will want to get serial samples from individuals at daily, or better weekly, or monthly intervals on representative persons in a control population.

Also, when you obtain blood from reference populations you will want to save both plasma and PBMC from those controls in the same manner that you are saving PBMCs from the HIV+ population. This will provide you with

materials collected under the same circumstances for the assays to be done subsequently on the stored PBMCs.

I think you deserve great congratulations for your plan of obtaining 50ml of blood on each of the testing dates. This should provide for current and future testing of both cells and plasma. I think this is setting important precedent for other clinical studies in Asia.

We look forward to seeing the data that you promised to send. We were intrigued with the fever charts and very impressed. They are striking and clearly illustrate what you mean by febrile episodes and indicate the extent of biologic response to the malarial parasites. The information on specific dates on when the chlocoquin is given and when subsequent blood samples are taken also help us to have a clear picture of the progress of the study. If the data that you already have on the WBC count, differential and the other data in a single table in the tabular format that we discussed and outlined on October 28th, it will certainly facilitate making judgments about tests where the results appeared to changed substantially during the malarial period as well as subsequently. We hope to be of assistance in this data analyses. The data for the CD4 and CD8 measurements obtained at the 1 month and 3 month time points after the end of malarial infection will also be interesting to see.

I greatly appreciated all the data you shared with us on this visit. I want to assure you that we regard this as confidential information. My colleagues and I will help with the analysis but not share it with others. You should report your result directly to Dr. Heimlich and not through me.

I want to congratulate you on organizing the data of the patients in the order from highest to lowest CD4 levels. That certainly facilitates discerning the types of changes that may occur in the different groups stratified by CD4 levels.

I believe that you have reagents for neopterin, soluble TNF α -receptor 2 and b2M measurements. We would be glad to provide reagents for additional tests after you have conducted tests for those parameters in November and December. We would prefer to defer sending additional reagents because we do not want the reagents to get out of date before you are able to use them. Thus, it would be better to send the reagents later on when your current test are completed.

The shipment of frozen plasma samples from Guangzhou to Los Angeles is certainly a high priority. We are checking into obtaining a shipping container for this. As soon as it is obtained, we will send it off to you.

Your assistance in answering all of our questions is much appreciated. They were designed to help us understand the study since we are some distance from all the action. We appreciate the dedication that you and your colleagues have to making this a successful study.

Sincerely,

John L. Fahey, M.D.
Director, CIRID at UCLA
Chair, Clinical Immunology Committee, International
Union of Immunological Societies (IUIS)
JLF/kw

cc: Barbara Hered
Najib Aziz, M.D.
Hong Bass, M.D., Ph.D.

UNIVERSITY OF CALIFORNIA, LOS ANGELES

UCLA

BERKELEY • DAVIS • IRVINE • LOS ANGELES • RIVERSIDE • SAN DIEGO • SAN FRANCISCO



SANTA BARBARA • SANTA CRUZ

Center for Interdisciplinary Research
in Immunology and Disease (CIRID)

November 6, 1998

Chen Xiao Ping, M.D.
Department of Microbiology
The Municipal Health and Anti-Epidemic Station of Guangzhou
No. 23, 3rd Zhongshan Rd.
Guangzhou 510080, P.R. China
Fax: (020)83815255

DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY
UCLA SCHOOL OF MEDICINE
CENTER FOR THE HEALTH SCIENCES
10833 LE CONTE AVENUE
LOS ANGELES, CALIFORNIA 90095-1747
(310) 825-6568
(310) 206-1318 (FAX)
jfahey@microimmun.med.sch.ucla.edu

Dear Dr. Chen,

I want to thank you very much for your kindness in providing such excellent assistance to Dr. Hong Z. Bass and myself during our visit on October 28th to you at the Municipal Health and Anti-Epidemic Station in Guangzhou. The two banquets were just marvelous. Once again, I appreciate the opportunity to enjoy the excellent Cantonese cuisine at Hubin Restaurant. The hotel accommodations were fine. We were able to get to the station in good time on the 29th and have a comfortable return trip to Hong Kong.

I was very impressed with all the progress you have made in your studies of malarial therapy in HIV infection. I think most people do not really appreciate how much work it is to carry out a clinical trial of this type. Extensive work is required to identify subjects, organize the study to begin at a certain date and have all the resources available including extensive clinical, laboratory and administrative support. Then to maintain continued follow-up contact, obtaining blood samples, seeing that appropriate analyses are done and that the data is collected is an enormous task. You have only a small staff to assist you in this. So, a great range of responsibilities fall directly on you. In addition, there are the challenges of seeing that all the laboratory tests are well developed and that suitable controls are being obtained and reference populations tested, e.g. those without HIV infection. This requires a variety of laboratory skills and technologies which you have organized in Guangzhou. They seem to be working effectively and I was impressed with the extensive data already obtained in the study.

Again, congratulations on developing such an interesting study and seeing that it is well underway. This study is sure to address a number of very important questions relating to HIV infection and to the novel approach of using malarial therapy. Clearly, the therapy is having an impact on the immune system and future tests on samples to be collected in coming months will establish the dimensions of changes on the immune parameters of HIV infection. My congratulations to those in the Municipal Health and Anti-epidemic Station of Guangzhou who have supported you in such a way as to make this important study possible.

Also, my thanks for your hospitality. I look forward to my next visit to Guangzhou.

Sincerely,

John L. Fahey, M.D.
Director, CIRID at UCLA
Chair, Clinical Immunology Committee, International
Union of Immunological Societies (IUIS)
JLF/kw

Subject:

Date: Tue, 17 Aug 1999 06:43:51 -0700

From: "John L. Fahey, M.D." <jlfahey@microimmun.medsch.ucla.edu>

To: Chen Xiao Ping <chenxp@gzsums.edu.cn>

CC: "heimlich@iglou.com" <heimlich@iglou.com>, "naziz@ucla.edu" <naziz@ucla.edu>

Center for Interdisciplinary Research
in Immunology and Disease (CIRID)

August 17, 1999

Chen Xiao Ping, M.D.
Department of Microbiology
The Municipal Health and Anti-Epidemic Station of Guangzhou
No. 23, 3rd Zhongshan Rd.
Guangzhou 510080, P.R. China

Dear Dr. Chen:

I want to acknowledge that I have your letter of June 8 and the information on the 9 month CD4 levels data for following malarial therapy for HIV/AIDS. Thank you for the table.

In evaluating CD4 change following malarial therapy, there are several questions: How many show a CD4 increase? Decrease? No change? Are CD4 changes transitory or sustained. What is the definition of significant change in number of CD4 T cells (100, 150 or 200 cells/mm³) or % (3, 4, 5 or ?). One way is to make it.

Because there is a substantial variability in serial measurements it is not appropriate to say that patients responded with sustained higher or lower levels of CD4 unless that change is verified. Thus, a confirmed directional change requires two sequential measurements documenting the increase or decrease in relation to baseline. Example of maintained lower levels of CD4 T cell levels might be patient 2 at band 9 months and patient 3 at 1, 3, 6 and 9 months. Examples of unchanged levels could be patients 3 and 10. The whole CD4% increase is seen in patient 5.

We can discuss the basis for selecting CD4 200/mm³ or 5% or some other level as markers of change when we get together in Hong Kong. The key lie in two portions of your own data. We can look at the two measurements before therapy in each of your 11 subjects. Also, we can look at your data on serial analyses in the same week of 5 normal subjects. We can review differences between measurements in these comparisons.

In usage the definition of an increase or decrease of 5% or of 200 cells/mm³ is partially presented by Kovacs, Lane, et al. in their New England Journal of Medicine papers, I think you have a copy of that paper. Also, in the ongoing ACTG 328 protocol evaluating therapeutic effects of IL-2, a change of that dimension is one of the criteria in the protocol design. This is a protocol we shared with you when you were here. However, you can establish other limits on the basis of the data that you have now accumulated. I hope this is helpful.

Sincerely,

John L. Fahey, M.D.
Director, CIRID at UCLA

Cc: Dr. Henry Heimlich
Dr. Najib Aziz

12/19/02 15:51 FAX 310 200 2350 COLA CAMERON COURSEL
Juno e-mail printed Sun, 10 Nov 2002 10:59:25 , page 1

From: chenxiaoping <chenxp@netease.com>
To: "Henry J. Heimlich, MD, ScD" <heimlich@juno.com>
Cc: "John L. Fahey, M.D." <jlfahey@microimmun.medsch.ucla.edu>
Date: Wed, 7 Feb 2001 9:32:23 +0800
Subject: Declaration letter to editor
Message-ID: <20010207013513.D4C9E1C45473B@smtp2.netease.com>
Received: from mx4.boston.juno.com (mx4.boston.juno.com [64.136.24.36])
by m1.boston.juno.com with SMTP id AAA7JBKTXA5AGKSA
for <heimlich@juno.com> (sender <chenxp@netease.com>);
Tue, 6 Feb 2001 20:34:45 -0500 (EST)
Received: from smtp2.netease.com ([202.103.134.9])
by mx4.boston.juno.com with SMTP id AAA7JBKTXAV5TVY2
for <heimlich@juno.com> (sender <chenxp@netease.com>);
Tue, 6 Feb 2001 20:34:45 -0500 (EST)
Received: from pc.gzsums.edu.cn (unknown [202.104.36.249])
by smtp2.netease.com (Postfix) with SMTP
id D4C9E1C45473B; Wed, 7 Feb 2001 09:35:13 +0800 (CST)
X-Mailer: FoxMail 3.0 beta 2 [cn]
MIME-Version: 1.0
Content-Type: text/plain; charset="GB2312"
Content-Transfer-Encoding: 7bit
Return-Path: <chenxp@netease.com>

Dear Dr. Heimlich,

Please you write a letter to declare that you agree to publish our paper
"Impact of acute vivax malaria on the immune system of HIV+ subjects".
The letter format should like as follow:

Dear Editor:

I declare that I participated in the work of the paper titled "Impact of
acute vivax malaria on the immune system of HIV+ subjects" written by
Chen XP, Heimlich HJ, Xiao BQ, Shi WJ, Xu HF, Gao K and Rao JL and that I
have seen and approve the final version. I also declare that I have no
conflict of interest in connection with this paper, other than any noted
in the covering letter to the editor.

Your signature (the signature need not be dated, in case the paper is not
accepted for publication so that it can be used for submission to another
journal.

Please mail this declaration letter to me by express as soon as you can
if you agree to publish this paper. If you have any idea to change the
contents and view points, please email me as soon as possible. Thank you.

Sincerely,

Chen, Xiao Ping, M.D.
Center for AIDS Control and Research
Municipal Health and Anti-Epidemic Station of GZ
chenxp@netease.com